Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JAK-2/3-IN-3 (化合物 ST4j) 可用于研究淋巴源性疾病和白血病。JAK-2/3-IN-3 以时间和剂量依赖性的方式抑制JAK2的自磷酸化并诱导细胞凋亡。JAK-2/3-IN-3 是 JAK2/3 的有效抑制剂,对JAK2和JAK3的IC50值分别为 13.00 和 14.86 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 10-14周 | ||
50 mg | ¥ 13,800 | 10-14周 | ||
100 mg | ¥ 17,500 | 10-14周 |
产品描述 | JAK-2-/3-IN-3 (compound ST4j) can be used in lymph derived diseases and leukemia research. JAK-2-/3-IN-3 inhibits JAK2 autophosphorylation and induces apoptosis in a time- and dose-dependent manner. JAK-2-/3-IN-3 is a potent inhibitor of JAK2/3 with IC50 values of 13.00 and 14.86 nM for JAK2 and JAK3, respectively [1]. |
体外活性 | JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells [1]. JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway [1]. JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells [1]. JAK-2/3-IN-3 (IC 25, IC 50, IC 75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells [1]. Apoptosis Analysis [1] Cell Line: TF1 cells Concentration: 15.53 μM Incubation Time: 24, 48, 72 h Result: Increased cells apoptotic by ~20%, ~40% and ~70%, after 24-, 48- and 72-h incubations, respectively. Increased cells apoptotic by ~15%, 20%, and 30% with concentration of IC 25, IC 50 and IC 75, respectively. Cell Cytotoxicity Assay [1] Cell Line: TF1, HEL, Vero and HepG2 cells Concentration: 0-100 μM Incubation Time: 72 h Result: Inhibited growth of TF1 and HEL cells, with IC 50 s of 15.53 and 17.90 μM. Showed low toxic to normal Vero cells and HepG2 cells (IC 50 of >100 μM in Vero cells and of >50 μM in HepG2 cells). |
分子量 | 325.15 |
分子式 | C13H10Cl2N4O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JAK-2/3-IN-3 Inhibitor inhibitor inhibit